<DOC>
	<DOCNO>NCT02749526</DOCNO>
	<brief_summary>Endostar ® ( recombinant human endostatin ) continuous intravenous infusion combine mPFC neoadjuvant treatment esophageal cancer arm , Ⅱ single-center clinical trial .</brief_summary>
	<brief_title>Endostar Combined With MPFC Adjuvant Treatment Esophageal Cancer Clinical Trial</brief_title>
	<detailed_description>1 . Research purpose : Endostar ( recombinant human endostatin ) continuous intravenous infusion combine chemotherapy stage Ⅲ resectable potentially resectable esophageal cancer efficacy safety maintain efficacy safety . 2 . The main objective : R0 resection rate Secondary objective : 1. pCR rate 2 . 3-year disease-free survival 3 . Security complication 4 . DFS , OS 5 . Quality Life 3.The number research center research time : This study intend preside implement Jiangsu Provincial People 's Hospital , Professor Gu Yanhong . The trial schedule start September 2015 , plan stop June 2016 group , one patient surgery follow-up last end , get primary endpoint safety , surgical complication secondary endpoint . This study continue follow-up patient DFS , OS secondary end point .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>patient esophageal cancer confirm histology cytology ; accord TNM stag Ⅲ period , previous untreated remove potentially resectable esophageal cancer patient ; eat liquid diet ; No sign esophageal perforation ; No distant metastasis ; male female , age 18 75 year old less ; ECOG PS 0 ~ 1 minute ; expect survive period 3 month , enough blood function : absolute neutrophil count ( ANC ) 2 x 109 / L • platelet count 100 x 109 / L high acuity 9 g/dL hemoglobin ; Liver function enough : upper limit total bilirubin acuity normal ( ULN ) ; AST ALT acuities 2.5 time upper limit normal ( ULN ) ; Alkaline phosphatase 5 time upper limit normal less ( ULN ) ; enough renal function , serum creatinine less normal limit ( ULN ) calculate creatinine clearance 60 mL/min . basic normal ecg , heal trauma ; always receive antitumor drug treatment ; ever surgery patient , request study treatment begin 4 week , patient recover ; complete uterus female group within 28 day study must negative pregnancy test result ( except amenorrhea 24 month ) .If pregnancy test first time 7 day , need urine pregnancy test validation ( within 7 day first delivery ) . prior biological agent , especially e. coli genetically engineer product without severe allergic reaction ; clear taxol allergy history ; pregnancy , nurse mother , fertility woman use contraception ; exist serious acute infection , control ; Or fester sex chronic infection , wound delay ; original serious heart disease , include : high risk congestive heart failure , unable control arrhythmia , unstable angina , myocardial infarction , severe valvular heart disease , resistant hypertension ; easy control nerve , mental illness mental disorder , compliance poor , ca n't cooperate account response treatment ; Primary brain tumor CNS metastases illness get control , obvious symptom cranial hypertension nerve spirit ; bleed tendency ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Recombinant human endostatin，Endo</keyword>
</DOC>